Effects of bile acids on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced aberrant crypt foci and DNA adduct formation in the rat colon.
The effects of deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced aberrant crypt foci (ACF) in the rat colon were examined. The effect of these bile acids on DNA adduct formation by PhIP in the colon was then analyzed, since the main action of PhIP is the formation of DNA adducts and subsequent gene mutations. For the ACF study, male F344 rats were administered PhIP-HCl (75 mg/kg, 10 doses) by gavage, and a diet containing bile acid (0.4% DCA or UDCA) was provided from 3 days before the first dose of PhIP for 8 weeks. The mean number of ACF per colon of DCA, UDCA and controls were 9.9, 2.4 and 5.5, respectively. The ACF number was significantly increased by DCA and decreased by UDCA (P<0.001). To examine the effect of bile acids on DNA adduct formation, male F344 rats were fed a diet supplemented with bile acids (0.1 or 0.4% of DCA and UDCA) 7 days prior to the PhIP administration. All rats were administered a single dose of PhIP-HCl (50 mg/kg) by gavage and sacrificed 48 hours later. DNA adduct levels of the 0.1% UDCA, 0.1% DCA and controls were 2.93 (adducts/10(7) nucleotides), 2.65 and 1.10, respectively. Those of 0.4% UDCA, 0.4% DCA and controls were 1.64, 1.30 and 1.00, respectively. The PhIP-DNA adduct level was significantly increased by administration of 0.1% UDCA, 0.1% DCA (P<0.05) and 0.4% UDCA (P<0.01). The increasing effect of both DCA and UDCA on PhIP-induced DNA adduct formation was unexpected, and was not directly associated with ACF formation.
Ueyama
Y
Y
Second Dept. of Surgery, School of Medicine, University of Tokushima, Tokushima, Japan.
Monden
Y
Y
He
X B
XB
Lin
C X
CX
Momen
M A
MA
Mimura
S
S
Umemoto
A
A
D000818:Animals; D002273:Carcinogens / Q000633:toxicity*; D003106:Colon / Q000187:drug effects / Q000473:pathology*; D018736:DNA Adducts; D003840:Deoxycholic Acid / Q000494:pharmacology*; D007093:Imidazoles / Q000633:toxicity*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology*; D008297:Male; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D051381:Rats; D011916:Rats, Inbred F344; D014580:Ursodeoxycholic Acid / Q000494:pharmacology*
D002273:Carcinogens; D018736:DNA Adducts; D007093:Imidazoles; D010972:Platelet Activating Factor; D003840:Deoxycholic Acid; D014580:Ursodeoxycholic Acid; C049584:2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine